Who is sponsoring NCT05363007?

NCT05363007 is sponsored by National Taiwan University Hospital.

What drugs are being tested in NCT05363007?

Interventions in NCT05363007: nanoliposomal irinotecan, spleen irradiation.

What condition does NCT05363007 study?

NCT05363007 studies Metastatic Pancreatic Cancer.

Is NCT05363007 still recruiting?

NCT05363007 is currently status unknown. Last updated 16 October 2023.

Last reviewed 2023-10-16 · How we verify

NCT05363007: SINAI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma

Status unknown Phase 2 Last updated 16 October 2023

What this trial tests

Phase 2 trial testing nanoliposomal irinotecan in Metastatic Pancreatic Cancer in 60 participants. Status unknown.

Timeline

1 May 2022

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	National Taiwan University Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 May 2022
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	2 locations across Taiwan

Drugs / interventions tested

nanoliposomal irinotecan — full drug profile →
spleen irradiation

Conditions studied

Metastatic Pancreatic Cancer — all drugs for Metastatic Pancreatic Cancer →

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 75, any sex, with Metastatic Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Splenomegaly is common in advanced pancreatic ductal adenocarcinoma (PDAC). The spleen is an important source of immune suppressive cells and phagocytic cells and may mediate the accumulation of liposomal drugs and immunosuppression. In this study, spleen irradiation (SI) will be added to standard chemotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeted spleen modulation: a novel strategy for next-generation disease immunotherapy.
Dong W, Li Y, Fei Q, Li S, et al · · 2025 · cited 16× · PMID 40225564 · DOI 10.7150/thno.111116

Verify or expand the search:

Other trials of nanoliposomal irinotecan

Trials testing the same drug.

NCT04088786 — Phase I Trial HIPEC With Nal-irinotecan · Phase 1 · completed
NCT03712397 — Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy · Phase 2 · completed
NCT02022644 — Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma · Phase 1 · completed

Other recruiting trials for Metastatic Pancreatic Cancer

Currently open trials in the same condition.

NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
NCT06843551 — The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation · Phase 2 · recruiting
NCT06951997 — QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer · Phase 2 · recruiting
NCT06533332 — A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors · Phase 1 · recruiting

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05363007 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 16 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05363007.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing